DARMSTADT, Germany - Thursday, 04. January 2024
First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer
Collaboration includes exclusive license outside the US with option to co-develop and co-promote ompenaclid in the US, as well as global co-development and co-commercialization rights for follow-on compounds
Strategic agreement builds on the heritage of ERBITUX® (cetuximab) and complements the company’s expertise and ongoing development programs in colorectal cancer
Not intended for UK-, US- or Canada-based media
(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced a licensing agreement with Inspirna
...
Read more »